JP5618461B2 - 癌の治療のための化合物および方法 - Google Patents

癌の治療のための化合物および方法 Download PDF

Info

Publication number
JP5618461B2
JP5618461B2 JP2007521685A JP2007521685A JP5618461B2 JP 5618461 B2 JP5618461 B2 JP 5618461B2 JP 2007521685 A JP2007521685 A JP 2007521685A JP 2007521685 A JP2007521685 A JP 2007521685A JP 5618461 B2 JP5618461 B2 JP 5618461B2
Authority
JP
Japan
Prior art keywords
cells
cancer
pharmaceutical composition
leukemia
mer1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007521685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008506710A (ja
JP2008506710A5 (enExample
Inventor
ラルフ エー． ジンガロ
ラルフ エー． ジンガロ
ハティージェ ダズケール
ハティージェ ダズケール
ジェイ． フライライヒエーミル
エーミル ジェイ． フライライヒ
ハゴップ カンタルジャン
ハゴップ カンタルジャン
メリダ ソテロ‐レルマ
メリダ ソテロ‐レルマ
ソルダム フェルストフセク
ソルダム フェルストフセク
ミンツァン ガオ
ミンツァン ガオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2008506710A publication Critical patent/JP2008506710A/ja
Publication of JP2008506710A5 publication Critical patent/JP2008506710A5/ja
Application granted granted Critical
Publication of JP5618461B2 publication Critical patent/JP5618461B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/72—Aliphatic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/74—Aromatic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/80—Heterocyclic compounds
    • C07F9/82—Arsenic compounds containing one or more pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2007521685A 2004-07-16 2005-07-15 癌の治療のための化合物および方法 Expired - Fee Related JP5618461B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58859604P 2004-07-16 2004-07-16
US60/588,596 2004-07-16
PCT/US2005/025192 WO2006020048A2 (en) 2004-07-16 2005-07-15 Compounds and methods for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011227543A Division JP2012051919A (ja) 2004-07-16 2011-10-17 癌の治療のための化合物および方法

Publications (3)

Publication Number Publication Date
JP2008506710A JP2008506710A (ja) 2008-03-06
JP2008506710A5 JP2008506710A5 (enExample) 2008-07-31
JP5618461B2 true JP5618461B2 (ja) 2014-11-05

Family

ID=35414967

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007521685A Expired - Fee Related JP5618461B2 (ja) 2004-07-16 2005-07-15 癌の治療のための化合物および方法
JP2011227543A Withdrawn JP2012051919A (ja) 2004-07-16 2011-10-17 癌の治療のための化合物および方法
JP2014037807A Expired - Lifetime JP5745660B2 (ja) 2004-07-16 2014-02-28 癌の治療のための化合物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011227543A Withdrawn JP2012051919A (ja) 2004-07-16 2011-10-17 癌の治療のための化合物および方法
JP2014037807A Expired - Lifetime JP5745660B2 (ja) 2004-07-16 2014-02-28 癌の治療のための化合物および方法

Country Status (11)

Country Link
US (2) US7405314B2 (enExample)
EP (1) EP1771459A2 (enExample)
JP (3) JP5618461B2 (enExample)
KR (5) KR20130001323A (enExample)
CN (3) CN101076533B (enExample)
AU (1) AU2005274926B2 (enExample)
CA (2) CA2574032C (enExample)
HK (1) HK1204476A1 (enExample)
IL (2) IL180729A (enExample)
TW (3) TW201440760A (enExample)
WO (1) WO2006020048A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014122233A (ja) * 2004-07-16 2014-07-03 Texas A & M Univ System:The 癌の治療のための化合物および方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2462932A1 (en) 2002-01-07 2012-06-13 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
US7628810B2 (en) 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
ES2532666T3 (es) 2005-07-29 2015-03-30 Solasia Pharma K.K. Compuestos y métodos para el tratamiento del cáncer
CN104109177A (zh) * 2006-01-13 2014-10-22 得克萨斯州A&M大学系统 用于治疗癌症的化合物和方法
RU2318519C2 (ru) * 2006-03-06 2008-03-10 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ химиотерапии острого лейкоза
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
KR20100100835A (ko) 2007-11-02 2010-09-15 지오팜 온콜로지 인코포레이티드 유기 비소제와의 병용 요법
CN104592302A (zh) * 2007-12-12 2015-05-06 日本苏爱康制药有限公司 用于治疗癌症的化合物和方法
RU2534606C2 (ru) 2008-08-20 2014-11-27 Зайофарм Онколоджи, Инк. Мышьякорганические соединения и способы лечения рака
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
CA2770735C (en) 2009-08-13 2017-07-18 Acufocus, Inc. Masked intraocular implants and lenses
US10004593B2 (en) 2009-08-13 2018-06-26 Acufocus, Inc. Intraocular lens with elastic mask
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
EP2785296B1 (en) 2011-12-02 2018-06-20 AcuFocus, Inc. Ocular mask having selective spectral transmission
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
TWI617305B (zh) * 2013-12-05 2018-03-11 蘇愛康制藥有限公司 治療癌症的化合物及其應用程序
GB201418491D0 (en) * 2014-10-17 2014-12-03 Monfort University De Compounds
WO2016081493A1 (en) 2014-11-19 2016-05-26 Acufocus, Inc. Fracturable mask for treating presbyopia
WO2017062316A1 (en) 2015-10-05 2017-04-13 Acufocus, Inc. Methods of molding intraocular lenses
EP3384342B1 (en) 2015-11-24 2021-08-25 AcuFocus, Inc. Toric small aperture intraocular lens with extended depth of focus
CN105330701B (zh) * 2015-11-27 2017-05-31 昆明医科大学 一种含砷化合物及其制备方法和应用
EP3790508A4 (en) 2018-05-09 2022-02-09 AcuFocus, Inc. INTRAOCULAR IMPLANT WITH REMOVABLE OPTICS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018798A1 (en) * 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) * 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
CN1443064A (zh) * 2000-04-26 2003-09-17 俄勒冈健康科学大学 施用含硫醇化学保护化合物的方法
EP2462932A1 (en) * 2002-01-07 2012-06-13 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014122233A (ja) * 2004-07-16 2014-07-03 Texas A & M Univ System:The 癌の治療のための化合物および方法

Also Published As

Publication number Publication date
KR20140136525A (ko) 2014-11-28
KR20130001323A (ko) 2013-01-03
JP2014122233A (ja) 2014-07-03
JP5745660B2 (ja) 2015-07-08
IL215896A0 (en) 2011-12-29
US20060128682A1 (en) 2006-06-15
CN101076533A (zh) 2007-11-21
TW201440760A (zh) 2014-11-01
JP2008506710A (ja) 2008-03-06
WO2006020048A2 (en) 2006-02-23
CA2777473A1 (en) 2006-02-23
TW201350113A (zh) 2013-12-16
CA2574032A1 (en) 2006-02-23
IL180729A0 (en) 2007-06-03
KR20070046120A (ko) 2007-05-02
CA2777473C (en) 2013-08-27
EP1771459A2 (en) 2007-04-11
AU2005274926A1 (en) 2006-02-23
TW200616615A (en) 2006-06-01
TWI411431B (zh) 2013-10-11
CN101076533B (zh) 2013-11-06
WO2006020048A3 (en) 2006-08-24
US7405314B2 (en) 2008-07-29
IL180729A (en) 2012-03-29
US20080090793A1 (en) 2008-04-17
JP2012051919A (ja) 2012-03-15
CN104163833A (zh) 2014-11-26
HK1204476A1 (en) 2015-11-20
KR101252866B1 (ko) 2013-04-10
CA2574032C (en) 2015-02-24
KR20130095857A (ko) 2013-08-28
CN105777811A (zh) 2016-07-20
AU2005274926B2 (en) 2011-04-28
WO2006020048B1 (en) 2006-10-19
KR20140013110A (ko) 2014-02-04

Similar Documents

Publication Publication Date Title
JP5745660B2 (ja) 癌の治療のための化合物および方法
JP5603593B2 (ja) 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン
US11324714B2 (en) Organoarsenic compounds and methods for the treatment of cancer
AU2011204901B2 (en) Compounds and methods for treatment of cancer
AU2007249110C1 (en) S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatment for cancer
HK1166959A (en) S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
HK1171952A (en) S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080612

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110715

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120229

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120530

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120628

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140916

R150 Certificate of patent or registration of utility model

Ref document number: 5618461

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees